Doxil®: The first fda-approved nanodrug-from an idea to a product (January 2015 update)

Yechezkel Barenholz

doi:10.4032/9789814669214

Doxil®: The first fda-approved nanodrug-from an idea to a product (January 2015 update)

Yechezkel Barenholz^*

^*Corresponding author for this work

Alexander Silberman Institute of Life Sciences

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

4 Scopus citations

Original language	English
Title of host publication	Handbook of Clinical Nanomedicine
Subtitle of host publication	Nanoparticles, Imaging, Therapy and Clinical Applications
Publisher	Pan Stanford Publishing Pte. Ltd.
Pages	827-906
Number of pages	80
Volume	1
ISBN (Electronic)	9789814669214
ISBN (Print)	9789814669207
DOIs	https://doi.org/10.4032/9789814669214
State	Published - 24 Feb 2016

Keywords

Anticancer
Biodistribution
Clinical trials
Delivery
Doxil®
Doxorubicin
Drug development
Drug release rate
Liposomes
Pegylated nano-liposomes
Pharmacokinetics
Therapeutic efficacy
Tumor targeting

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4032/9789814669214

Cite this

@inbook{4289f7bf11b4400db296b3bf2f512d28,

title = "Doxil{\textregistered}: The first fda-approved nanodrug-from an idea to a product (January 2015 update)",

keywords = "Anticancer, Biodistribution, Clinical trials, Delivery, Doxil{\textregistered}, Doxorubicin, Drug development, Drug release rate, Liposomes, Pegylated nano-liposomes, Pharmacokinetics, Therapeutic efficacy, Tumor targeting",

author = "Yechezkel Barenholz",

year = "2016",

month = feb,

day = "24",

doi = "10.4032/9789814669214",

language = "אנגלית",

isbn = "9789814669207",

volume = "1",

pages = "827--906",

booktitle = "Handbook of Clinical Nanomedicine",

publisher = "Pan Stanford Publishing Pte. Ltd.",

}

TY - CHAP

T1 - Doxil®

T2 - The first fda-approved nanodrug-from an idea to a product (January 2015 update)

AU - Barenholz, Yechezkel

PY - 2016/2/24

Y1 - 2016/2/24

KW - Anticancer

KW - Biodistribution

KW - Clinical trials

KW - Delivery

KW - Doxil®

KW - Doxorubicin

KW - Drug development

KW - Drug release rate

KW - Liposomes

KW - Pegylated nano-liposomes

KW - Pharmacokinetics

KW - Therapeutic efficacy

KW - Tumor targeting

UR - http://www.scopus.com/inward/record.url?scp=85015937740&partnerID=8YFLogxK

U2 - 10.4032/9789814669214

DO - 10.4032/9789814669214

M3 - ???researchoutput.researchoutputtypes.contributiontobookanthology.chapter???

AN - SCOPUS:85015937740

SN - 9789814669207

VL - 1

SP - 827

EP - 906

BT - Handbook of Clinical Nanomedicine

PB - Pan Stanford Publishing Pte. Ltd.

ER -

Doxil®: The first fda-approved nanodrug-from an idea to a product (January 2015 update)

Keywords

UN SDGs

Access to Document

Other files and links

Cite this